Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
Authors:
Open Access
- 15 April 2017
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 49 (2) , 399-407
Abstract
The tertiary lymphoid structure (TLS) is an important source of tumor-infiltrating lymphocytes (TILs), which have a strong prognostic and predictive value in triple-negative breast cancer (TNBC). A previous study reported that the levels of CXCL13 mRNA expression were associated with TLSs, but measuring the gene expression is challenging in routine practice. Therefore, this study evaluated the MECA79-positive high endothelial venule (HEV) densities and their association with the histopathologically assessed TLSs in biopsy samples. In addition, the relationship of TLSs with the CXCL13 transcript levels and clinical outcomes were examined. A total of 108 TNBC patients treated with neoadjuvant chemotherapy (NAC) were studied. The amounts of TILs and TLSs were measured histopathologically using hematoxylin and eosin-stained slides. The HEV densities and TIL subpopulations were measured by immunohistochemistry for MECA79, CD3, CD8, and CD20. CXCL13mRNA expression levels using a NanoString assay (NanoString Technologies). The mean number of HEVs in pre-NAC biopsies was 12 (range, 0 to 72). The amounts of TILs and TLSs, HEV density, and CXCL13 expression showed robust correlations with each other. A lower pre-NAC clinical T stage, higher TIL and TLS levels, a higher HEV density, CD20-positive cell density, and CXCL13 expression were significant predictors of a pathologic complete response (pCR). Higher CD8-positive cell density and levels of CXCL13 expression were significantly associated with a better disease-free survival rate. MECA79-positive HEV density in pre-NAC biopsies is an objective and quantitative surrogate marker of TLS and might be a valuable tool for predicting pCR of TNBC in routine pathology practice.Keywords
Funding Information
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning (2015R1C1A1A02036484)
This publication has 28 references indexed in Scilit:
- Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerJournal of Pathology and Translational Medicine, 2015
- Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant TrastuzumabAmerican Journal of Clinical Pathology, 2015
- Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsTherapeutic Advances in Medical Oncology, 2013
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer PatientsJournal of Breast Cancer, 2013
- HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodesNature Reviews Immunology, 2012
- High endothelial venules (HEVs) in human melanoma lesionsOncoImmunology, 2012
- Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancerBreast Cancer Research, 2011
- Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast CancerCancer Research, 2011
- Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanomaCancer, 1996
- Lymphocyte infiltrates as a prognostic variable in female breast cancerEuropean Journal of Cancer, 1992